
Categories
The EU identified vaccines as a priority in the response to the COVID-19 pandemic early on in the pandemic, and started focusing on the development of a safe and efficient vaccine as a solution to ending the health crisis. By November 2021, the Commission had signed €71 billion worth of contracts on behalf of the Member States to purchase up to 4.6 billion vaccine doses. Pfizer/BioNTech vaccine dominates the portfolio in 2022-2023 because of the company’s ability to reliably supply the EU.